are
mainly prescribed for high–CVD-risk patients.
The purpose of this investigation was to determine the
effect of 2 dosing schedules of pantethine vs placebo on
blood cholesterol values over a 16-week treatment period for
North American subjects in ATP III CVD risk groups 1 and 2
(initially nonstatin candidates) immediately following a
4-week TLC diet lead-in.are
mainly prescribed for high–CVD-risk patients.
The purpose of this investigation was to determine the
effect of 2 dosing schedules of pantethine vs placebo on
blood cholesterol values over a 16-week treatment period for
North American subjects in ATP III CVD risk groups 1 and 2
(initially nonstatin candidates) immediately following a
4-week TLC diet lead-in.